Literature DB >> 1325044

Radiation maculopathy after proton beam irradiation for choroidal melanoma.

D R Guyer1, S Mukai, K M Egan, J M Seddon, S M Walsh, E S Gragoudas.   

Abstract

PURPOSE: Radiation maculopathy is a microangiopathy of the retina, which is often observed after irradiation of the eye. To quantitatively determine the frequency of anatomic and functional features of this condition, the authors reviewed a large series of patients with choroidal melanomas who were treated by proton beam irradiation.
METHODS: Color photographs and/or fluorescein angiograms of 218 patients with paramacular choroidal melanomas were graded by two independent masked readers to determine the frequency of the various lesions of radiation maculopathy.
RESULTS: Overall, 194 (89%) of the 218 patients in this study developed some degree of radiation maculopathy. The earliest and most common finding was macular edema, which was observed in 87% of patients, overall, by the end of year 3. Microvascular changes (microaneurysms and/or telangiectasia), intraretinal hemorrhages, and capillary nonperfusion were noted in 76%, 70%, and 64% of eyes, respectively, by the end of postirradiation year 3. Visual acuity was retained at 20/200 or better in 90% of eyes 1 year after irradiation and in 67% of eyes 3 years after treatment.
CONCLUSION: Radiation maculopathy is common after proton beam irradiation of paramacular choroidal melanomas. However, ambulatory vision is preserved in many eyes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325044     DOI: 10.1016/s0161-6420(92)31832-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  25 in total

1.  Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration.

Authors:  Rupan Trikha; Lawrence S Morse; Robert J Zawadzki; John S Werner; Susanna S Park
Journal:  Retina       Date:  2011 Jul-Aug       Impact factor: 4.256

2.  Application of intravitreal bevacizumab for circumscribed choroidal hemangioma.

Authors:  Min Sagong; Junyeop Lee; Woohyok Chang
Journal:  Korean J Ophthalmol       Date:  2009-06-09

3.  Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.

Authors:  Henrike Wuestemeyer; Wolfgang Sauerwein; Daniel Meller; Pierre Chauvel; Andreas Schueler; Klaus-Peter Steuhl; Norbert Bornfeld; Gerasimos Anastassiou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

4.  Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy.

Authors:  P T Finger; M Kurli
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

5.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

6.  Long-term follow-up after uveal melanoma charged particle therapy.

Authors:  D H Char; S M Kroll; J Castro
Journal:  Trans Am Ophthalmol Soc       Date:  1997

7.  Development and validation of a patient based measure of outcome in ocular melanoma.

Authors:  A J Foss; D L Lamping; S Schroter; J Hungerford
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

8.  Intraocular inflammation after proton beam irradiation for uveal melanoma.

Authors:  L Lumbroso; L Desjardins; C Levy; C Plancher; E Frau; F D'Hermies; P Schlienger; H Mammar; S Delacroix; C Nauraye; R Ferrand; C Desblancs; A Mazal; B Asselain
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

9.  Photocoagulation treatment for clinically significant radiation macular oedema.

Authors:  J L Kinyoun; R W Zamber; B S Lawrence; W E Barlow; A M Arnold
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

10.  I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

Authors:  H Culver Boldt; B Michele Melia; Judy C Liu; Sandra M Reynolds
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.